Research programme: Cushing's syndrome therapy - Samaritan Pharmaceuticals

Drug Profile

Research programme: Cushing's syndrome therapy - Samaritan Pharmaceuticals

Alternative Names: SP-6300

Latest Information Update: 16 Jul 2009

Price : $50

At a glance

  • Originator Georgetown University
  • Developer Samaritan Pharmaceuticals
  • Class
  • Mechanism of Action HMG-CoA reductase inhibitors; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cushing syndrome

Most Recent Events

  • 16 Jul 2009 Samaritan is seeking a partnership to further develop SP 6300 (
  • 16 Jul 2009 An IND is active for SP 6300 for the treatment of Cushing's syndrome in US
  • 21 Sep 2007 US FDA approves IND application for SP 6300 in Cushing's syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top